A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel ... PharmCast, 2 weeks ago
1 images for "lacosamide"
Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal …
/PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: ...Yahoo! Finance, 3 weeks ago Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability Digital Journal, 1 month ago PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis TickerTech.com, 1 month ago
MarketReserachReports.com: Global Epilepsy Market Value to Reach $4.5 Billion by 2019 Due to Recent Drug Approvals
The epilepsy therapeutics market value in the eight major countries - the US, Canada, France, Germany, Italy, Spain, the UK and Japan - will increase from $3.4 billion in 2012 to $4.5 billion by 2019, at a modest Compound Annual Growth Rate (CAGR) ...Individual.com, 1 month ago MarketReserachReports.com: Asia-Pacific Epilepsy Therapeutics Market Continues to Grow as New Drugs Emerge Individual.com, 1 month ago Market Research Reports, Inc. (www.marketresearchreports.com): MarketReserachReports.com: Global Epilepsy Market Value to Reach $4.5 Billion by 2019 Due to Recent Drug Approvals BusinessWeek, 1 month ago Global epilepsy market to reach $4.5 billion by 2019 Pharma Letter, 1 month ago
/PRNewswire/ -- ReportsnReports.com offers "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability" and "NSCLC Therapeutics in Asia-Pacific Markets to ...TickerTech.com, 1 month ago
UCB SA expects that global demand for its core neurology and immunology products will deliver solid growth in 2014 as the company makes the transition to new management. Jean-Christophe Tellier, a rheumatologist and currently executive vice ...MedNous, 1 month ago UCB posts solid set of results for 2013 Pharma Times, 1 month ago Core products boost UCB 2013 sales, but profits disappoint Pharma Letter, 1 month ago UCB promotes from within for new CEO Pharma Times, 1 month ago
The UK biotechnology industry has missed the boat and not fulfilled its potential, according to outgoing UCB chief executive Roch Doliveux. Speaking to journalists at the announcement of UCB's financial results for 2013, Doliveux said that the UK ...Pharmafocus, 1 month ago
Back to Top | Article Outline ARTICLE IN BRIEF Figure Image Tools Investigators reported that patients with status epilepticus receiving intravenous anesthetic drugs (IVADs) had a higher proportion of infection and an increased risk ...Neurology Today, 1 month ago
on your WebpageAdd Widget >Get your members hooked!